BeyondSpring is trading at $0.67, up 7.89%, with no company-specific catalyst identified.
- Biotech was up 2.13% and major indexes were sharply higher, making broader strength a plausible contributor; no source confirmed the direct cause.
- September’s FDA Fast Track and trial-funding announcement is prior news, not a confirmed explanation for this move.
- BeyondSpring’s November 3 session had fallen 22.94%, following volatile recent trading.